Stem cell therapy in India is emerging as a new modality within the healthcare system. The progress is supported by numerous innovators within the country. One company forging the way is ReeLabs, a leading stem cell bank in India that is supporting the collection and storage of stem cells, as well as the development of novel stem cell therapeutics.
Diabetes Mellitus in India
According to the World Health Organization (WHO), diabetes mellitus (DM), commonly referred to as diabetes, is a group of metabolic disorders in which there are high blood sugar levels over a prolonged period. Diabetes mellitus is one of the most common diseases globally.
In India, the prevalence of diabetes is rising, predominantly related to factors such as genetic factors, stress, diet, obesity, lack of meaningful exercise and lifestyle related issues.
ReeLabs, a Leading Stem Cell Bank in India
Cord blood banking in India is of growing importance, because the country has a population of 1.3 billion and is projected to surpass China as the world’s most populous country by 2024. India’s population growth is fueled by a birth rate (19 births/1,000 population) that substantially exceeds its death rate (7.3 deaths/1,000 population).
India also has a fertility rate of 2.4 births per woman, making it important to provide high-quality stem cell banking services for newborns.
Over the past 10 years, ReeLabs has emerged as one of the largest stem cell company in the region. In addition to storing human stem cells from 10 different sources and providing stem cell therapy for over 100 disorders, ReeLabs supports a R&D center that regularly channels funds and resources in devising stem cell-related technologies.
ReeLabs as a Stem Cell Therapy Center
As stated by Dr. Abhijit Bopardikar MD, Director or ReeLabs: “The purpose of starting ReeLabs was to have a world class, sophisticated enterprise that could effectively deal with stem cell banking (from all available human sources), therapy using these cells, and meaningful research and clinical trials using these cell types.”
Dr. Bopardikar also states: “ReeLabs offers stem cell treatment for various chronic, degenerative diseases, including Autism, Cerebral Palsy, Chronic Kidney Diseases, Chronic Liver Diseases, Cardiovascular diseases, Diabetes Type 1 and 2, ALS, Multiple Sclerosis, Spinal cord injury, stroke, Muscular Dystrophy, Parkinson’s disease, Alzheimer’s disease, Macular Degeneration, Retinitis Pigmentosa, Osteoarthritis, Pulmonary Fibrosis, Interstitial Lung Disease, Hair-loss and Anti-aging.”
ReeLabs Patents and Expertise
ReeLabs has filed two international patents dealing with applications of stem cells in the field of clinical medicine and have launched clinical trials using allogeneic stem cells from:
- Umbilical cord blood
- Umbilical cord tissue
- Foetal (abortus) material
Additionally, it is the only company in India with extensive expertise with banking stem cells from the placenta, a valuable source of immunologically-privileged cells.
Did you know?
Banking the Amniotic fluid and Placental stem cells along with Cord tissue and Cord blood encompasses the entire scope of stem cell banking options available during childbirth. In fact, childbirth is the most valuable source of amniotic fluid and amniotic sac. pic.twitter.com/2c2UZrjdBo
— Reelabs (@ReeLabs) July 3, 2018
ReeLabs’ Foetal Progenitor Cells
ReeLabs has notable scientists from the Ukraine on their panel who helped devise a novel method of treatment using foetal progenitor cells from an abortus of 14 to 20 weeks. The results have been excellent, and the company has filed five patents, as well as initiated clinical trials using this breakthrough technology.
According to multiple studies, these cells show a strong safety profile safe with no tumorogenicity and the results appear promising compared to other cellular products under research for use to treat diabetes mellitus. According to leadership at ReeLabs, its foetal progenitor cell treatments works effectively against both Type 1 and Type 2 Diabetes.
The company has paired with numerous prominent maternity centers, where mothers are thoroughly screened prior to their samples getting accepted. With the rising number of pregnancies and abortions in India, procurement of the ‘perfectly appropriate sample’ for trials is accessible and convenient.
According to Dr. Abhijit Bopardikar, MD, Director or ReeLabs: “Unlike our peers, we are committed to take these clinical trials to culmination. It shall be our contribution to society to work toward eliminating diabetes mellitus and other devastating diseases.”
To learn more about stem cell therapy in India, read our interviews with:
- ReeLabs, Cord Blood Banking in India | Interview with Dr. Bopardikar
- CEO Mayur Srisimal: On LifeCell and India Cord Blood Bank Industry
Do you have questions about how ReeLabs is approaching stem cell treatments in India? Ask them in the comments below.